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Abstract
Anti-NMDA-Receptor encephalitis is a severe form of encephalitis that was recently identified in the context of
acute neuropsychiatric presentation. Here, we describe the case of a 17-year-old girl referred for an acute mania
with psychotic features and a clinical picture deteriorated to a catatonic state. Positive diagnosis of anti-NMDA-
receptor encephalitis suggested specific treatment. She improved after plasma exchange and immunosuppressive
therapy. Post-cognitive sequelae (memory impairment) disappeared within 2-year follow-up and intensive cognitive
rehabilitation.
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Background
NMDA receptors are ligand-gated cation channels that
play an important role in synaptic plasticity [1] and seem
to be implicated in the physiopathology of neuropsychia-
tric disorders [2]. NMDA receptors are heteromers of
NR1 and NR2 subunits (A, B, C or D) that bind glycine
and glutamate, respectively [3]. Both glycine and gluta-
mate must bind for the NMDA receptor to be functional.
Anti-NMDA-receptor encephalitis has been recently
identified. The antibodies found in anti-NMDA-receptor
encephalitis are directed against the NR1 subunit of the
NMDA receptor [4].
The clinical syndrome of a paraneoplastic neuropsy-
chiatric disorder associated with ovarian teratoma was
first described in 2005 [5], and Dalmau and colleagues
identified and described the specific antibody in 2007 [6].
Since then, several case reports of anti-NMDA-receptor
encephalitis have been published, suggesting that this ill-
ness is not rare [4,7-11]. In 2008, Dalmau and al. pub-
lished a series of 100 cases of anti-NMDA-Receptor
encephalitis [12]. Recently, the same group reported on
more than 400 patients with anti-NMDA-Receptor
encephalitis over a 3-year period [4]. The exact incidence
of anti-NMDAR encephalitis is unknown, but it seems to
be more frequent than any other known paraneoplastic
encephalitis [4]. It predominantly affects children and
young adults and may occur with or without tumor asso-
ciation [4]. Eighty percent of the patients are women.
The clinical syndrome is now clearly described. First, a
brief viral-like episode (e.g., headache, hyperthermia) can
occur. This is followed by an acute phase that includes
neuropsychiatric symptoms such as agitation, psychotic
symptoms (i.e., delusions or hallucinations), behavioral
changes, generalized or partial seizures, progressive unre-
sponsiveness, abnormal movements (e.g., dyskinesia),
dysautonomy and hypoventilation that can require venti-
lation assistance and intensive care. The frequency of
tumors varies according to age, sex and ethnicity [4].
Usually teratoma of the ovaries in women or testicular
tumors in men that express NMDA-R which triggers
antibody production, are found [13].
For patients with anti-NMDA-Receptor encephalitis,
magnetic resonance imaging (MRI) scans are often nor-
mal or show only minor, non-specific signs. Patients’
cerebrospinal fluid (CSF) may show pleocytosis and an
elevated protein concentration. In addition, patients’
electroencephalogram (EEG) results exhibit diffuse slow
activity. Despite a severe initial presentation, complete
or near complete recovery can be reached using
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ever, severe sequelae and even death occur in up to 25%
of all cases [12].
In this paper, we present a case report of a 17-year-
old girl referred for acute mania with psychotic features
and malignant catatonia due to anti-NMDA-Receptor
encephalitis. She was first treated empirically with
immunosuppressive therapy and plasma exchange (PE)
for presumed immune mediated encephalitis based on
increased antinuclear antibodies. Treatment was then
continued based on the diagnosis of anti-NMDA-R
encephalitis.
Case Presentation
A 17-year-old girl with no medical, psychiatric or surgical
history began exhibiting symptoms of hypochondriasis.
Her parents reported that she had sudden changes of
mood, becoming more irritable and sensitive. In a few
days, she began to get worse. She presented manic symp-
toms with psychomotor excitement, logorrhea, tachypsy-
chia, euphoric state and insomnia. She had delusions and
hallucinations with dysmorphophobic and nosophobic
thematics. She also presented with one generalized sei-
zure, although she did not suffer from epilepsy.
The patient was transferred to the closest psychiatric
department where she presented with catatonia syndrome
without extrapyramidal signs. She was given olanzapine
(40 mg/day), loxapine (50 mg/day) and clonazepam
(3.5 mg/day). She soon showed malignant catatonia with
autonomic instability, fever, arterial hypertension and CPK
increase (4500 UI/L) and was transferred to the university
department of adolescent psychiatry. Antipsychotic medi-
cations were stopped, and a high dosage of lorazepam
(15 mg/day) was started. Because of her life-threatening
condition, the patient was transferred to an intensive care
unit. Dysautonomy and fever improved, but she remained
catatonic, showing rigidity, mutism, staring, waxy flexibil-
ity and negativism. An exhaustive biological check-up was
conducted to rule out possible organic causes (i.e., immu-
nological, infectious, metabolic, iatrogenic and toxic) [14].
An examination of her cerebral spinal fluid revealed eight
cells, and an electroencephalogram showed diffuse slow
waves (0.5 to 1 wave per second); antinuclear factors were
positive (1/320), but anti-DNA antibodies were not. A
Magnetic Resonance Imaging (MRI) scan showed subtle,
small and non-specific hyperintensities (Figure 1). A cere-
bral positron emission tomography (
18FDG-PET) revealed
left frontal-temporal cortex hypometabolism and moder-
ate bilateral hippocampic hypometabolism (Figure 2).
Electroconvulsive therapy (ECT) was postponed due to
arguments supporting hypothesis of acute encephalitis
(seizures, EEG signs and brain hypometabolism). Based on
suspicion of neuropsychiatric systemic lupus erythemato-
sus (SLE) (because of positive antinuclear factors and
neurological symptoms), immuno-suppressive therapy was
initiated. For 3 days, she received prednisone at a dose of
1 g IV. This was followed by a month of 1 mg/kg/day oral
prednisone, which was progressively decreased. Two
weekly pulses of cyclophosphamide (0.7 g/m
2)a n d1 3
plasma exchanges were also given. Antiepileptic treatment
was added to the immunosuppressive treatment given the
recent general seizures in the context of encephalitis.
Catatonia as well as affective and psychotic symptoms
progressively improved, but the patient revealed many
neurological sequelae. Indeed, she presented with frontal
lobe syndrome (perseverations, grasping, lack of emo-
tions, lack of initiative, speech reduction and aphasia),
severe impairment of memory, ataxia, stereotyped move-
ments (e.g., chewing movements and teeth grinding),
right ptosis and myosis. Early neuropsychological and
speech testing confirmed the presence of frontal-like
aphasia with perseverations, significant slowness, severe
verbal and non-verbal impairment, major memory
impairment (in short term and working memory) with
confabulations. Furthermore, she was anosognosic. Her
cognitive functions were clearly abnormal given her age
and school level before this episode (Table 1).
After the neurological sequelae indicated an encephalo-
pathy with frontal and limbic dysfunction, we evaluated
her serum and cerebrospinal fluid for an increase in anti-
NMDA-Receptor antibodies. These levels were highly
elevated. The anti-NMDA-Receptor encephalitis diagno-
sis was therefore retained, yet no tumor was found. The
patient was transferred to a recovery center, where she
received speech therapy and cognitive remediation for
her memory loss. Immunosuppressive treatment with
intravenous immunoglobulin was prescribed for the next
months (Table 1), and she continued to improve. Post-
cognitive sequelae disappeared within 2 years. Subse-
quently, she was able to return to school and seemed to
have regained her original cognitive abilities (Table 1).
Conclusions
In this case report, acute mania with psychotic features
deteriorating to catatonic state revealed anti-NMDA-recep-
tor encephalitis. This encephalitis is a multistage illness
that progresses from psychosis, memory deficits, seizures,
and language disintegration to a state of unresponsiveness
with catatonic features [4]. Psychiatric symptoms, including
delusions, anxiety, insomnia, and mania, can occur initially,
and they usually present less than 2 weeks after prodromal
symptoms (headache, fever, nausea, diarrhea or upper
respiratory tract symptoms) [4]. The patients are often
initially seen by psychiatrists. Anti-NMDA-Receptor ence-
phalitis predominantly affects children and young adults
[4,13] and may or may not be associated with a tumor.
Approximately 80% of patients are women. The presence
of a tumor is more frequent in women who are older than
Consoli et al. Child and Adolescent Psychiatry and Mental Health 2011, 5:15
http://www.capmh.com/content/5/1/15
Page 2 of 618 years and who are black [4]. Because of the initial psy-
chiatric presentation, high dosages of antipsychotics were
administrated to the patient. Even if the role of antipsycho-
tics is not clear and that catatonic features occur in anti-
NMDA-Receptor encephalitis, they may aggravate the cata-
tonic symptoms.
Therapeutic approaches to catatonia are mainly symp-
tomatic. It is recommended to use high dosages of ben-
zodiazepines and to perform electroconvulsive therapy
in case of resistance or a life threatening condition [15].
Treatment of the causal organic condition is also war-
ranted. In this case, the patient did not respond to high
doses of lorazepam. ECT was discussed but postponed
due to signs of acute encephalitis.
A recent literature review showed that organic causes of
catatonia in young people make up 20% of all cases [14],
and this rate was confirmed in a prospective study [16].
Among the organic causes, encephalitis, caused by infec-
tion or immune mechanisms requires specific treatments.
In particular, neuropsychiatric systemic lupus erythemato-
sus (SLE) can be revealed by a catatonic syndrome. It is
crucial to diagnose and begin an appropriate treatment
quickly to improve the patient’s prognosis. Plasma
exchange appears to be an efficient treatment option in
SLE and catatonia, and it avoids the use of ECT [17,18].
In the present case, given the increased antinuclear anti-
bodies, the MRI results (non-specific white matter hyperin-
tensities) and the PET hypometabolism, clinicians first
hypothesized the presence of SLE. The presence of antinuc-
lear and/or thyroid peroxidase antibodies, in addition to
NMDAR antibodies, has been previously described, most
typically in children and can suggest a predisposition to this
type of auto immunity [4,13]. Associated plasma exchanges
and immunosuppressive therapy were used as treatment.
After improvement of the malignant catatonia, neurological
markers led to a diagnosis of anti-NMAD-receptor ence-
phalitis, which indicated the need for continuation of
immunomodulatory therapy with immunoglobulins. This
treatment led to a major improvement in catatonic, psy-
chiatric and neurological symptoms. Management of anti-
NMDAR encephalitis is focused on immunotherapy and
the detection and removal of a teratoma [4]. Based on an
extensive review (400 patients over a 3-year period),
Dalmau and colleagues proposed an algorithmic strategy to
guide treatment [4]. The first line of immunotherapy con-
sists of corticosteroids, intravenous immunoglobulins, and
plasma exchange (alone or in combination). The second
line of immunotherapy (rituximab or cyclophosphamide or
both) is usually needed in the case of a delayed diagnosis or
in the absence of a tumor [4].
Figure 1 Small and non-specific hyperintensities in Magnetic Resonance Imaging (MRI).
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receptors are known to play a crucial role in synaptic
plasticity, which is involved in memory, learning and
cognition [19]. Disruption of these receptors can result
in seizures and changes in memory, learning and beha-
vior [1]. It is possible to explain the patient’ss e q u e l a e
by a diagnosis of diffuse encephalopathy that is mainly
due to frontal and limbic dysfunction. Similarly, an early
manifestation with acute severe psychiatric signs and
catatonia may be related to dysfunction of the NMDA-R
circuitry, as the NMDA-R has been implicated in psy-
chotic symptomatology [20,21].
Interestingly, another case of adolescent catatonia
associated with encephalitis has been reported [22]. In
that case, encephalitis was paraneoplastic and improved
after an ovarian tumor ablation. In retrospect, it is pos-
s i b l et h a tt h a tc a s ea l s op r e s e n t e dw a sa n t i - N M D A -
receptor encephalitis, given its frequent association with
ovarian teratoma [12,13]. Another recent case report
showed an excellent recovery after immunotherapy
(plasma exchange and corticosteroids) in a case of anti-
NMDAR encephalitis in a 12-year-old girl [23].
Recognition of encephalitis by psychiatrists is impor-
tant because patients may initially present with psychia-
tric symptoms and catatonic features. Here, symptoms
and paraclinical data are in accordance with cases of anti
NMDAR encephalitis already reported: severe psychiatric
symptoms, seizures, orofacial dyskinesia. In the case of
severe and possible life-threatening anti-NMDA-receptor
encephalitis, it is essential that a quick and adapted treat-
ment is implemented. Indeed, the prognosis of anti
NMDA-R encephalitis varies: 75% of cases recover with
immunotherapy and tumor ablation (when present),
while 25% of cases lead to severe sequelae and even
death [4]. Relapse occurs in 15% of all cases [12].
This case report emphasizes the importance to search for
a medical condition in catatonic syndrome of young people
to treat and avoid severe neurological sequelae or death.
The proposal of the DSM-V workgroup to make catatonia
a “specifier” added as a fifth digit to other diagnoses seems
Figure 2 ZZ
Figure 2 Left frontal-temporal cortex hypometabolism and moderate bilateral hippocampic hypometabolism in cerebral positron
emission tomography (
18FDG-PET).
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importance of recognizing this syndrome and researching
for medical condition, particularly during psychiatric train-
ing. By contrast, a large group of experts advocated a
unique and broadly-defined code for catatonia as a syn-
drome, which can be diagnosed acutely in addition to any
suspected or established associated disorders [24]. In this
case, the initial psychiatric clinical presentation was com-
plicated by a malignant catatonic state, which is now well-
described in anti-NMDA-Receptor encephalitis. Child psy-
chiatrists need to know that anti-NMDA-Receptor ence-
phalitis occurs frequently in children and adolescents.
Plasma exchanges and immunosuppressive therapy treat-
ments can dramatically improve catatonic syndrome asso-
ciated with autoimmune dysfunction such as SLE [17,18],
PANDAS [25] and NMDA-receptor encephalitis.
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PE = Plasma exchange; IQ = Intellectual Quotient; WAIS = Wechsler Adult Intelligence Scale.
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